Boosting Cancer Immunotherapy with Nanomedicines: Novel Approaches and Promising Clinical Applications
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Clinical Pharmaceutics".
Deadline for manuscript submissions: closed (30 July 2024) | Viewed by 522
Special Issue Editors
Interests: nanomedicine; biology; cancer therapy
Special Issue Information
Dear Colleagues,
We are pleased to invite you to contribute to a Special Issue entitled “Boosting Cancer Immunotherapy with Nanomedicines: Novel Approaches and Promising Clinical Applications”.
Tumors are conventionally treated by surgery, chemotherapy, and radiotherapy. However, tumor relapse and poor quality of life are forcing us to explore novel and complementary strategies. Targeting the immune system is becoming a valuable clinical approach, both as a first and second line of treatment for several malignancies. Different immunotherapy strategies have been proposed and are undergoing clinical evaluation including monoclonal antibodies, cancer vaccines, checkpoint inhibitors, cells therapies (chimeric antigen receptor (CAR) T cells, dendritic cell vaccine), and non-specific cancer immunotherapies (interleukins, cytokines, interferons, and others). Despite the clinical relevance of some of these strategies, many patients still experience limited efficacy and significant toxicity. Nanomedicines were originally designed to boost the uptake of cytotoxic agents by tumor cells and reduce off-target deleterious effects. Following the same principle, nanomedicines can be engineered to deliver immunological agents to the desired target site and reprogram the immune response.
This Special Issue aims to provide an update on the development of injectable and implantable systems for the precise delivery of immune modulators and cytotoxic molecules. The Special Issue will take into consideration the most recent approaches designed for both the systemic and the local delivery of agents targeting cancer cells, the tumor immune microenvironment, or the peripheral immune system. Moreover, the Special Issue is aimed at dissecting the mechanisms of interaction between nanomedicines and the immune system, and the technological and regulatory challenges that could limit the clinical translation of nanomedicine-based immunotherapies.
In this Special Issue, high-impact original research articles and reviews regarding the most recent progress in nanomedicine-based immunotherapy are welcome. Research areas may include (but are not limited to) the following:
- Systemic targeting of tumors by intravenously administered nanomedicines;
- Devices for the local delivery and sustained release of immunomodulatory drugs;
- Control of immunostimulation and spatio-temporal heterogeneity;
- Radiotherapy and immunotherapy;
- Chemotherapy and immunotherapy;
- Gene therapy and immunotherapy;
- Nanomaterials for immunotherapy.
We look forward to receiving your contributions.
Dr. Anna Lisa Palange
Prof. Dr. Paolo Decuzzi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- nanomedicine
- systemic and local delivery
- spatio-temporal heterogeneity
- gene therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
